Clinical evaluation of linezolid in 15 cases of severe lung infections caused by methicillin-resistant Staphylococcus aureus
- VernacularTitle:利奈唑胺治疗耐甲氧西林金黄色葡萄球菌重症肺炎15例
- Author:
Tao XU
;
Li YU
;
Junhui YANG
;
Ding LONG
;
Yuanchao ZHANG
;
Feng GENG
- Publication Type:Journal Article
- Keywords:
linezolid;
methicillin-resistant Staphylococcus aureus;
inflammation;
lactic acid;
inflammatory cytokine
- From:
Chinese Journal of Infection and Chemotherapy
2009;09(4):264-266
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of linezolid in the treatment of severe lung infections caused by methicillin-resistant Staphylococcus aureus (MRSA).Methods Fifteen patients admitted to ICU due to severe lung infection caused by MRSA received linezolid treatment. WBC, lactic acid (LAC), IL-1β, IL-6, and TNF-α levels were measured before and after treatment. Results Clinical efficacy rate was 73.3%. The level of WBC, LAC and inflammatory cytokines decreased significantly after linezolid treatment (P<0.01).Conclusions Linezolid shows good efficacy in the treatment of severe lung infections caused by MRSA.
